<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743574</url>
  </required_header>
  <id_info>
    <org_study_id>YaleU-0807003992</org_study_id>
    <secondary_id>YCCI-CARE Grant #UL1RR024139</secondary_id>
    <nct_id>NCT00743574</nct_id>
  </id_info>
  <brief_title>Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)</brief_title>
  <official_title>Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a prospective un-blinded pilot study of Vitamin D plus Calcium
      (Ca) supplementation in overweight (BMI &gt; 27) premenopausal women diagnosed with Polycystic
      Ovarian Syndrome (PCOS), as defined by the Rotterdam Criteria, 2003, and who were deficient
      in vitamin D as reflected by serum 25-hydroxy (25-OH) vitamin D (serum levels &lt; 20 ng/mL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We had hypothesized that in women with PCOS, administering optimal daily doses of vitamin D3,
      as recommended by the National Academy of Sciences, 2000IU Cholecalciferol and 1000mg of
      calcium, both per oral (PO), over a three month period will improve their metabolic picture,
      and possibly hormone profile.

      Over the course of the trial, after the first 5 subjects had completed 3 month
      intervention,we observed that daily 2000IU D3 dosing regime was inadequate in normalizing
      vitamin D status in the study population; the dosing regimen was therefore modified to
      include weekly supplementation with 50,000IU D2 in addition to daily dosing with 2000IU D3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Were Assessed at Study Completion After 3 Month Treatment</measure>
    <time_frame>Completion</time_frame>
    <description>Fasting HbA1C levels at study completion after 3 month treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Insulin Levels at Study Completion After 3 Month Treatment</measure>
    <time_frame>3 months intervention</time_frame>
    <description>Fasting insulin levels at study completion after 3 month treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Glucose Levels at Completion of Treatment, at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting glucose levels drawn after 3 months completion during oral GTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area Under a Curve at 0, 0.5, 1, 1.5 and 2 Hours) Insulin During 2 Hour GTT at Completion, at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Following 3 months intervention, AUC insulin was determined during 2 hour oral GTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area Under the Curve at 0, 0.5, 1, 1.5 and 2 Hours) During Oral GTT at Completion, at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)for glucose was determined at completion of 3 months intervention for 2 hour oral GTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of C-reactive Protein at Completion of 3 Months Treatment Compared to Baseline.</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of C-reactive protein upon completion, at 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D plus Calcium (Ca) supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D2 (Ergocalciferol)</intervention_name>
    <description>50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)</description>
    <arm_group_label>Vitamin D plus Calcium (Ca) supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone (Provera)</intervention_name>
    <description>10mg, PO, daily for ten days</description>
    <arm_group_label>Vitamin D plus Calcium (Ca) supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 (Cholecalciferol)</intervention_name>
    <description>2,000IU (or 2 tablets), PO, daily (supplements taken for three months)</description>
    <arm_group_label>Vitamin D plus Calcium (Ca) supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Elemental Calcium</intervention_name>
    <description>1,000mg (or 2 tablets), PO, daily (supplements taken for three months)</description>
    <arm_group_label>Vitamin D plus Calcium (Ca) supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women (ages 18-40 years) with normal thyroid function and prolactin
             levels.

          -  PCOS diagnosis based on Rotterdam criteria: presence of at least 2 of the following
             criteria:

               -  oligomenorrhea-menstrual cycles &gt; 35 day intervals

               -  hyperandrogenemia (elevated serum testosterone [free or total] &amp;/or
                  androstenedione levels) or features of hyperandrogenism i.e. acne or hirsuitism
                  [Ferriman-Gallaway score &gt; 3]

               -  polycystic ovaries on vaginal ultrasound as defined by ESHRE/ASRM criteria
                  (ovarian volume ≥ 10mL or ≥ 12 follicles of diameter between 2-9mm in at least
                  one ovary)

               -  Overweight (BMI ≥ 27 Kg/m2)

               -  Biochemical evidence of Vitamin D insufficiency (i.e. serum 25 OHD levels &lt;
                  20ng/mL)

        Exclusion Criteria:

          -  Pregnancy

          -  Known causes of oligomenorrhea other than PCOS, e.g. hypothyroidism/Cushing's
             Disease/late onset congenital adrenal hyperplasia (fasting 17-alphahydroxyprogesterone
             levels &lt; 200ng/dL)

          -  Use of hormonal treatment (birth control pill/patch/depot
             medroxyprogesterone/medroxyprogesterone) within 3 months of the study onset.

          -  Use insulin sensitizers (metformin, sulfonylureas, TZDs, incretins) within 3 months of
             the study onset.

          -  Use of lipid lowering agents or medications known to influence insulin sensitivity
             (e.g. niacin, corticosteroids, beta blockers, calcium channel blockers, thiazide
             diuretics) or influence serum androgens (estrogen, anti-androgens, androgens) within 3
             months of the study onset.

          -  Known history of renal calculi or current use of Calcium and Vitamin D supplements.

          -  Spanish Speaking.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubna Pal, MBBS,MRCOG,MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital-Women's Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, Taylor H. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol. 2012 Dec;28(12):965-8. doi: 10.3109/09513590.2012.696753. Epub 2012 Jul 11.</citation>
    <PMID>22780885</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <results_first_submitted>February 15, 2013</results_first_submitted>
  <results_first_submitted_qc>June 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2013</results_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Lubna Pal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited through flyers, medical clinics, internet postings May 2008-February 2010</recruitment_details>
      <pre_assignment_details>Some subjects did not follow through with eligibility testing or had further exclusions, such as scheduling difficulties.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
          <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dropped Out Before Eligibility Testing</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Further Exclusions</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dropped Out After Initiating Trial</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>the number of participants for analysis was determined by the number who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
          <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.42" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1C levels</title>
          <description>Fasting HbA1C levels were collected at baseline during a 2 hour oral Glucose Tolerance Test (GTT)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.37" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline insulin levels</title>
          <description>Fasting insulin levels at baseline were drawn during an oral GTT</description>
          <units>µIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.92" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline glucose levels</title>
          <description>Fasting glucose levels at baseline were drawn during an oral GTT</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.79" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline AUC insulin</title>
          <description>Fasting AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)insulin was drawn at baseline during a oral GTT</description>
          <units>µIU/ml/120 min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16136.50" spread="10086.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline AUC for glucose</title>
          <description>Fasting level for AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)glucose at baseline was drawn based on oral GTT</description>
          <units>mg/min/120min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16648.41" spread="3949.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline C Reactive protein level</title>
          <description>Fasting levels of Creactive protein levels were drawn during oral GTT</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.72" spread="1.51-13.93" lower_limit="1.51" upper_limit="13.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of C-reactive Protein at Completion of 3 Months Treatment Compared to Baseline.</title>
        <description>Serum levels of C-reactive protein upon completion, at 3 months</description>
        <time_frame>3 months</time_frame>
        <population>All subjects who completed treatment for 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of C-reactive Protein at Completion of 3 Months Treatment Compared to Baseline.</title>
          <description>Serum levels of C-reactive protein upon completion, at 3 months</description>
          <population>All subjects who completed treatment for 3 months</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1.52" upper_limit="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Were Assessed at Study Completion After 3 Month Treatment</title>
        <description>Fasting HbA1C levels at study completion after 3 month treatment</description>
        <time_frame>Completion</time_frame>
        <population>Number determined by those who completed all interventions and procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Were Assessed at Study Completion After 3 Month Treatment</title>
          <description>Fasting HbA1C levels at study completion after 3 month treatment</description>
          <population>Number determined by those who completed all interventions and procedures.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Insulin Levels at Study Completion After 3 Month Treatment</title>
        <description>Fasting insulin levels at study completion after 3 month treatment</description>
        <time_frame>3 months intervention</time_frame>
        <population>Number determined by all those who completed all interventions and procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Levels at Study Completion After 3 Month Treatment</title>
          <description>Fasting insulin levels at study completion after 3 month treatment</description>
          <population>Number determined by all those who completed all interventions and procedures.</population>
          <units>µIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.17" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose Levels at Completion of Treatment, at 3 Months</title>
        <description>Fasting glucose levels drawn after 3 months completion during oral GTT</description>
        <time_frame>3 months</time_frame>
        <population>Number determined based on all interventions and procedures completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Levels at Completion of Treatment, at 3 Months</title>
          <description>Fasting glucose levels drawn after 3 months completion during oral GTT</description>
          <population>Number determined based on all interventions and procedures completed.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.79" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Area Under a Curve at 0, 0.5, 1, 1.5 and 2 Hours) Insulin During 2 Hour GTT at Completion, at 3 Months</title>
        <description>Following 3 months intervention, AUC insulin was determined during 2 hour oral GTT</description>
        <time_frame>3 months</time_frame>
        <population>Number determined by completion of all study interventions and procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Area Under a Curve at 0, 0.5, 1, 1.5 and 2 Hours) Insulin During 2 Hour GTT at Completion, at 3 Months</title>
          <description>Following 3 months intervention, AUC insulin was determined during 2 hour oral GTT</description>
          <population>Number determined by completion of all study interventions and procedures</population>
          <units>µIU/ml/120min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16715.57" spread="10371.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Area Under the Curve at 0, 0.5, 1, 1.5 and 2 Hours) During Oral GTT at Completion, at 3 Months</title>
        <description>AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)for glucose was determined at completion of 3 months intervention for 2 hour oral GTT</description>
        <time_frame>3 months</time_frame>
        <population>Number determined by all participants who completed all interventions and procedures</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
            <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Area Under the Curve at 0, 0.5, 1, 1.5 and 2 Hours) During Oral GTT at Completion, at 3 Months</title>
          <description>AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)for glucose was determined at completion of 3 months intervention for 2 hour oral GTT</description>
          <population>Number determined by all participants who completed all interventions and procedures</population>
          <units>mg/min/120min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16726.56" spread="3941.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D Plus Calcium (Ca) Supplementation</title>
          <description>Vitamin D3 (Cholecalciferol) : 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Elemental Calcium : 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Vitamin D2 (Ergocalciferol) : 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Medroxyprogesterone (Provera) : 10mg, PO, daily for ten days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lubna Pal</name_or_title>
      <organization>Yale University</organization>
      <phone>203-737-5619</phone>
      <email>lubna.pal@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

